BelimumabA Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Sponsor:

GlaxoSmithKline

Code:

NCT05878717

Conditions

Systemic Sclerosis Associated Interstitial Lung Disease

Scleroderma, Systemic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Belimumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2026-01-12.